Market Research Report

A quick peek into the report

1.1   Market Outlook
1.1.1   Definitions
1.1.2   Inclusion and Exclusion Criteria
1.1.3   Market Size, 2024 - 2035 (US$)
1.1.4   Market Growth Scenario
1.1.4.1   Realistic Scenario
1.1.4.2   Optimistic Scenario
1.1.4.3   Pessimistic Scenario
1.2   Industry Outlook
1.2.1   Market Overview
1.2.2   Market Ecosystem
1.2.3   Key Trends
1.2.4   Opportunity Assessment
1.2.5   Regulatory Landscape
1.2.6   Reimbursement Scenario
1.3   Market Dynamics
1.3.1   Market Opportunities and Trends
1.3.2   Market Drivers
1.3.2.1   Impact Analysis
1.3.3   Market Restraints
1.3.3.1   Impact Analysis
1.3.4   Market Challenges
1.3.4.1   Impact Analysis

2.1   Presymptomatic and Predictive testing
2.2   Carrier Screening Test
2.2.1   Expanded Carrier Screening
2.2.2   Targeted Carrier Screening
2.3   Non-Invasive Prenatal Test
2.4   Preimplantation Genetic Testing (PGT)
2.5   Newborn Screening

3.1   Next Generation Sequencing (NGS)
3.2   Microarray
3.3   FISH
3.4   PCR
3.5   Others

4.1   Oncology
4.2   Cardiovascular Disease
4.3   Reproductive Health
4.4   Neurodegenerative diseases
4.5   Rare Disease
4.6   Others

5.1   Hospitals
5.2   Clinics
5.3   Direct to Consumer (DTC)
5.4   Others

6.1   Market Overview
6.1.1   Market Dynamics
6.1.2   Market Size and Forecast
6.1.2.1   North America Genetic Screening Testing for Preventive Health Market
6.1.2.1.1   U.S.
6.1.2.1.2   Canada.
6.1.2.2   Europe Genetic Screening Testing for Preventive Health Market
6.1.2.2.1   U.K.
6.1.2.2.2   Germany.
6.1.2.2.3   France
6.1.2.2.4   Italy.
6.1.2.2.5   Spain
6.1.2.2.6   Rest of Europe.
6.1.2.3   Asia Pacific Genetic Screening Testing for Preventive Health Market
6.1.2.3.1   China
6.1.2.3.2   Japan
6.1.2.3.3   India
6.1.2.3.4   Australia
6.1.2.3.5   South Korea
6.1.2.3.6   Rest of Asia Pacific
6.1.2.4   Latin America Genetic Screening Testing for Preventive Health Market
6.1.2.4.1   Brazil
6.1.2.4.2   Mexico
6.1.2.4.3   Rest of Latin America
6.1.2.5   Middle East and Africa Genetic Screening Testing for Preventive Health Market
6.1.2.5.1   UAE
6.1.2.5.2   South Africa
6.1.2.5.3   Rest of MEA

7.1   Competitive Benchmarking
7.2   Competitive Landscape
7.2.1   Key Strategies and Developments by Company
7.2.1.1   Funding Activities
7.2.1.2   Mergers and Acquisitions
7.2.1.3   Regulatory Approvals
7.2.1.4   Partnerships, Collaborations, and Business Expansions
7.2.2   Key Developments Analysis
7.3   Company Profiles
7.3.1   Exact Science
7.3.1.1   Company Overview
7.3.1.2   Product Portfolio/Offering
7.3.1.3   Key Competitors
7.3.1.4   Target Customers/End Users
7.3.1.5   Analyst View
7.3.2   Labcorp Genetics Inc.
7.3.2.1   Company Overview
7.3.2.2   Product Portfolio/Offering
7.3.2.3   Key Competitors
7.3.2.4   Target Customers/End Users
7.3.2.5   Analyst View
7.3.3   Blueprint Genetics
7.3.3.1   Company Overview
7.3.3.2   Product Portfolio/Offering
7.3.3.3   Key Competitors
7.3.3.4   Target Customers/End Users
7.3.3.5   Analyst View
7.3.4   Ambry Genetics
7.3.4.1   Company Overview
7.3.4.2   Product Portfolio/Offering
7.3.4.3   Key Competitors
7.3.4.4   Target Customers/End Users
7.3.4.5   Analyst View
7.3.5   Genex Diagnostics Inc.
7.3.5.1   Company Overview
7.3.5.2   Product Portfolio/Offering
7.3.5.3   Key Competitors
7.3.5.4   Target Customers/End Users
7.3.5.5   Analyst View
7.3.6   Sonic Healthcare
7.3.6.1   Company Overview
7.3.6.2   Product Portfolio/Offering
7.3.6.3   Key Competitors
7.3.6.4   Target Customers/End Users
7.3.6.5   Analyst View
7.3.7   Dante Labs US
7.3.7.1   Company Overview
7.3.7.2   Product Portfolio/Offering
7.3.7.3   Key Competitors
7.3.7.4   Target Customers/End Users
7.3.7.5   Analyst View
7.3.8   Myriad Genetics, Inc.
7.3.8.1   Company Overview
7.3.8.2   Product Portfolio/Offering
7.3.8.3   Key Competitors
7.3.8.4   Target Customers/End Users
7.3.8.5   Analyst View
7.3.9   Revvity
7.3.9.1   Company Overview
7.3.9.2   Product Portfolio/Offering
7.3.9.3   Key Competitors
7.3.9.4   Target Customers/End Users
7.3.9.5   Analyst View
7.3.10   Laboratory Corporation of America Holdings
7.3.10.1   Company Overview
7.3.10.2   Product Portfolio/Offering
7.3.10.3   Key Competitors
7.3.10.4   Target Customers/End Users
7.3.10.5   Analyst View
7.3.11   23andMe
7.3.11.1   Company Overview
7.3.11.2   Product Portfolio/Offering
7.3.11.3   Key Competitors
7.3.11.4   Target Customers/End Users
7.3.11.5   Analyst View
7.3.12   BGI Group
7.3.12.1   Company Overview
7.3.12.2   Product Portfolio/Offering
7.3.12.3   Key Competitors
7.3.12.4   Target Customers/End Users
7.3.12.5   Analyst View
7.3.13   CENTOGENE N.V.
7.3.13.1   Company Overview
7.3.13.2   Product Portfolio/Offering
7.3.13.3   Key Competitors
7.3.13.4   Target Customers/End Users
7.3.13.5   Analyst View
7.3.14   Fulgent Genetics.
7.3.14.1   Company Overview
7.3.14.2   Product Portfolio/Offering
7.3.14.3   Key Competitors
7.3.14.4   Target Customers/End Users
7.3.14.5   Analyst View
7.3.15   Quest Diagnostics Incorporated.
7.3.15.1   Company Overview
7.3.15.2   Product Portfolio/Offering
7.3.15.3   Key Competitors
7.3.15.4   Target Customers/End Users
7.3.15.5   Analyst View
7.3.16   Progenesis
7.3.16.1   Company Overview
7.3.16.2   Product Portfolio/Offering
7.3.16.3   Key Competitors
7.3.16.4   Target Customers/End Users
7.3.16.5   Analyst View
7.3.17   CooperSurgical
7.3.17.1   Company Overview
7.3.17.2   Product Portfolio/Offering
7.3.17.3   Key Competitors
7.3.17.4   Target Customers/End Users
7.3.17.5   Analyst View
7.3.18   Illumina
7.3.18.1   Company Overview
7.3.18.2   Product Portfolio/Offering
7.3.18.3   Key Competitors
7.3.18.4   Target Customers/End Users
7.3.18.5   Analyst View
7.3.19   Igenomix
7.3.19.1   Company Overview
7.3.19.2   Product Portfolio/Offering
7.3.19.3   Key Competitors
7.3.19.4   Target Customers/End Users
7.3.19.5   Analyst View
7.3.20   Agilent Technologies, Inc.
7.3.20.1   Company Overview
7.3.20.2   Product Portfolio/Offering
7.3.20.3   Key Competitors
7.3.20.4   Target Customers/End Users
7.3.20.5   Analyst View
7.3.21   Other Key Companies
7.3.21.1   Company Overview
7.3.21.2   Product Portfolio/Offering
7.3.21.3   Key Competitors
7.3.21.4   Target Customers/End Users
7.3.21.5   Analyst View

Genetic Screening Testing for Preventive Health Market Report Coverage

Genetic Screening Testing for Preventive Health Market
Base Year	2024	Market Size in 2025	$XX Billion
Forecast Period	2025-2035	Value Projection and Estimation by 2035	$XX Billion
CAGR During Forecast Period	XX%

How can this report add value to an organization?

Product/Innovation Strategy: This report provides a comprehensive product/innovation strategy for the genetic screening testing for preventive health market, identifying opportunities for market entry, technology adoption, and sustainable growth. It offers actionable insights, helping organizations to meet environmental standards, gain a competitive edge, and capitalize on the increasing demand for eco-friendly solutions in various industries.

Growth/Marketing Strategy: This report offers a comprehensive growth and marketing strategy designed specifically for the genetic screening testing for preventive health market. It presents a targeted approach to identifying specialized market segments, establishing a competitive advantage, and implementing creative marketing initiatives aimed at optimizing market share and financial performance. By harnessing these strategic recommendations, organizations can elevate their market presence, seize emerging prospects, and efficiently propel revenue expansion.

Competitive Strategy: This report crafts a strong competitive strategy tailored to the genetic screening testing for preventive health market. It evaluates market rivals, suggests methods to stand out, and offers guidance for maintaining a competitive edge. By adhering to these strategic directives, companies can position themselves effectively in the face of market competition, ensuring sustained prosperity and profitability.

Introduction to Genetic Screening Testing for Preventive Health Market

Genetic screening testing for preventive health involves analyzing an individual’s genetic makeup to predict the likelihood of developing certain diseases or conditions in the future. These screenings are designed to identify genetic predispositions to various health issues, such as heart disease, cancer, diabetes, and other hereditary disorders. The market for genetic screening testing in preventive health has been experiencing rapid growth, driven by driving factors such as technological advancements, increased consumer interest in personalized medicine, and the rise of preventive healthcare strategies.

Genetic tests for preventive health can range from identifying specific gene mutations to assessing an individual’s risk for chronic diseases. These tests help individuals take proactive steps to manage their health and potentially reduce the risk of developing conditions through early lifestyle changes or medical interventions. The preventive health market includes genetic tests for common conditions and rare genetic disorders and carrier screening for inherited diseases.

Several key factors influence the expansion of the genetic screening testing for preventive health market. Improvements in genetic testing technologies, such as next-generation sequencing (NGS), have made these tests more accessible, cost-effective, and accurate. Growing consumer awareness of the benefits of early detection, rising healthcare costs, and an increasing focus on prevention have further fuelled the demand.

Moreover, the increasing availability of direct-to-consumer genetic tests has allowed individuals to manage their health. Stakeholders in this market include genetic testing companies, healthcare providers, hospitals, diagnostic laboratories, and wellness-focused organizations. As more people seek personalized, data-driven approaches to healthcare, the demand for genetic screenings as a preventive tool is expected to increase. Moreover, the growing availability of direct-to-consumer genetic testing kits has empowered individuals to take charge of their health and gain insights into their genetic predispositions without necessarily needing a healthcare provider. This trend has significantly expanded the genetic screening market, allowing consumers to access preventive health information more easily.

The genetic screening testing for preventive health market is set to witness substantial growth. With continued technological advancements and growing public interest in health optimization and disease prevention, the market offers significant opportunities for healthcare, biotechnology, and wellness stakeholders to meet the rising demand for personalized, proactive health solutions. The development of next-generation sequencing (NGS) technologies and improvements in bioinformatics have made genetic testing more accurate, efficient, and affordable. These innovations allow for comprehensive genetic analysis, enhancing the ability to detect predispositions to various diseases at earlier stages. The continuous evolution of these technologies further drives the demand for genetic screening services in preventive healthcare.

Furthermore, there is a growing recognition of the importance of preventive healthcare, with more individuals understanding the benefits of early disease detection and management. Public health campaigns, medical professionals, and organizations have been emphasizing the value of genetic screening to detect health risks before symptoms appear, further driving market demand.

Key players in the market are Exact Science, Labcorp Genetics Inc., Blueprint Genetics, Ambry Genetics, Genex Diagnostics Inc., Sonic Healthcare, Dante Labs US, Myriad Genetics, Inc., Revvity, Laboratory Corporation of America Holdings, BGI Group, Fulgent Genetics.

Market Segmentation:

Segmentation 1: by Test Type
•    Carrier Screening Test
     o    Expanded Carrier Screening
     o    Targeted Carrier Screening
•    Non-Invasive Prenatal Test
•    Preimplantation Genetic Testing
•    Newborn Screening

Segmentation 2: by Technology
• NGS
• Microarray
• PCR
• FISH
• Others

Segmentation 3: by Application
• Oncology
• Cardiovascular Diseases
• Reproductive Health
• Neurodegenerative Health
• Rare Diseases
• Others

Segmentation 4: by End User
• Hospitals and Diagnostic Laboratories
• DTC Companies
• Genetic Counselling Services
• Other End Users

Segmentation 5: by Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

•   North America holds the largest share in the genetic screening testing for preventive health market, primarily driven by technological advancements, robust healthcare infrastructure, and high consumer awareness. The U.S., in particular, is a key player due to its well-established healthcare system, extensive research on genetic testing, and a growing focus on personalized medicine. Additionally, the availability of direct-to-consumer genetic testing companies, such as 23andMe, has increased market penetration.
•   Europe is also a major market for genetic screening, with countries like the United Kingdom, Germany, and France investing heavily in preventive healthcare. The European market is characterized by a high demand for genetic tests related to cancer, cardiovascular diseases, and neurological conditions. The region benefits from strong healthcare policies that encourage genetic testing.
•   The Asia-Pacific region has been experiencing significant growth in the genetic screening testing for preventive health market, driven by increasing healthcare awareness, rising incomes, and growing investment in healthcare infrastructure. Countries such as China, India, Japan, and South Korea are emerging as key markets for genetic testing. While India and China have large populations with diverse genetic profiles, Japan and South Korea are leading the way in terms of advanced healthcare technologies.
•   The Middle East and Africa region presents emerging opportunities for genetic screening, with growing interest in healthcare advancements and genetic testing. The UAE, Saudi Arabia, and South Africa are leading the region's adoption of preventive health measures, including genetic screenings, although economic and infrastructure barriers persist in some areas.

The genetic screening testing for preventive health market is diverse and multifaceted, with segmentation across test types, applications, end-users, and regions. This segmentation highlights the growing demand for personalized and proactive healthcare solutions, driven by advances in genetic testing technologies and increased awareness of the benefits of early disease detection. As the market continues to expand, key players in the healthcare and biotechnology sectors can leverage these segments to offer tailored services that meet the specific needs of different demographics and regions.Preventive health measures in this region are becoming a priority as the region faces a rise in chronic diseases such as diabetes, cancer, and cardiovascular diseases. Public health initiatives in countries such as Japan and Singapore are emphasizing preventive care, further supporting the adoption of genetic screening.